Notable Healthcare Headlines for the Week: UnitedHealth, Eli Lilly, J&J in Focus
Baird Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $118
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
Short Bets Against S&P 500 Healthcare Stock Rises in March; MRNA Stays Top Shorted
Charles River Associates (CRA) to Host First-Quarter Fiscal 2025 Financial Results Conference Call on May 1
Express News | Charles River Laboratories International Inc : Baird Raises Target Price to $118 From $101
Why Investors Shouldn't Be Surprised By Charles River Laboratories International, Inc.'s (NYSE:CRL) 38% Share Price Plunge
Sell-rated S&P 500 Stocks as per Seeking Alpha's Quant Model
Trump Signs Executive Order on Drug Pricing
Trump Seeks Ideas to Reduce Prescription Drug Costs
Press Release: Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $105
BofA Securities Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $150
Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.
① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.
Trump Opened Pharmaceutical, Semiconductor Tariff Probes April 1
Charles River Laboratories International Inc. Stock Rallies 6.9%, Outperforms Competitors
Unusual Options Activity: TGT, V and Others Attract Market Bets, TGT V/OI Ratio Reaches 35.5
TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating
BofA Securities Cuts Charles River Laboratories International Price Target to $150 From $185
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing